GH
Guardant Health, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$155.56
−3.40%Year over year
Reported trailing growth
- Revenue
- +42.7%
- EBITDA
- -11.6%
- EBIT
- -2.1%
- EPS
- -4.2%
- Free cash flow
- +11.4%
- Operating cash flow
- +22.4%
Forward estimates
Based on analyst estimates
- Revenue
- +31.3%
- EBITDA
- +23.0%
- EPS
- +19.0%
Three-year CAGR
- Revenue
- +29.8%
- EBITDA
- +4.2%
- EBIT
- +1.4%
- Net income
- +4.6%
- EPS
- +6.7%
- Free cash flow
- +15.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026